Janux Therapeutics Inc. (JANX)
Janux Therapeutics Statistics
Share Statistics
Janux Therapeutics has 59.11M shares outstanding. The number of shares has increased by 11.88% in one year.
| Shares Outstanding | 59.11M |
| Shares Change (YoY) | 11.88% |
| Shares Change (QoQ) | 10.8% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 49.57M |
| Failed to Deliver (FTD) Shares | 3.54K |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
The latest short interest is 8.55M, so 14.8% of the outstanding shares have been sold short.
| Short Interest | 8.55M |
| Short % of Shares Out | 14.8% |
| Short % of Float | 17.89% |
| Short Ratio (days to cover) | 8.41 |
Valuation Ratios
The PE ratio is -41.71 and the forward PE ratio is -18.85. Janux Therapeutics's PEG ratio is 13.76.
| PE Ratio | -41.71 |
| Forward PE | -18.85 |
| PS Ratio | 271.8 |
| Forward PS | 4.5 |
| PB Ratio | 2.81 |
| P/FCF Ratio | -65.15 |
| PEG Ratio | 13.76 |
Enterprise Valuation
Janux Therapeutics Inc. has an Enterprise Value (EV) of 477.63M.
| EV / Earnings | -6.92 |
| EV / Sales | 45.11 |
| EV / EBITDA | -4.83 |
| EV / EBIT | -4.83 |
| EV / FCF | -10.81 |
Financial Position
The company has a current ratio of 59.21, with a Debt / Equity ratio of 0.02.
| Current Ratio | 59.21 |
| Quick Ratio | 59.21 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.2 |
| Cash Flow / Debt | -1.9 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.07% and return on capital (ROIC) is -9.45%.
| Return on Equity (ROE) | -0.07% |
| Return on Assets (ROA) | -0.06% |
| Return on Capital (ROIC) | -9.45% |
| Revenue Per Employee | $130,716.05 |
| Profits Per Employee | $-851,777.78 |
| Employee Count | 81 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -21.01% in the last 52 weeks. The beta is 3.22, so Janux Therapeutics's price volatility has been higher than the market average.
| Beta | 3.22 |
| 52-Week Price Change | -21.01% |
| 50-Day Moving Average | 35.98 |
| 200-Day Moving Average | 44.78 |
| Relative Strength Index (RSI) | 37.92 |
| Average Volume (20 Days) | 962.52K |
Income Statement
In the last 12 months, Janux Therapeutics had revenue of 10.59M and earned -68.99M in profits. Earnings per share was -1.28.
| Revenue | 10.59M |
| Gross Profit | 10.59M |
| Operating Income | -98.85M |
| Net Income | -68.99M |
| EBITDA | -98.85M |
| EBIT | -98.85M |
| Earnings Per Share (EPS) | -1.28 |
Balance Sheet
The company has 430.61M in cash and 23.02M in debt, giving a net cash position of 407.58M.
| Cash & Cash Equivalents | 430.61M |
| Total Debt | 23.02M |
| Net Cash | 407.58M |
| Retained Earnings | -237.76M |
| Total Assets | 1.06B |
| Working Capital | 1.02B |
Cash Flow
In the last 12 months, operating cash flow was -43.81M and capital expenditures -359K, giving a free cash flow of -44.17M.
| Operating Cash Flow | -43.81M |
| Capital Expenditures | -359K |
| Free Cash Flow | -44.17M |
| FCF Per Share | -0.82 |
Margins
Gross margin is 100%, with operating and profit margins of -933.58% and -651.62%.
| Gross Margin | 100% |
| Operating Margin | -933.58% |
| Pretax Margin | -651.62% |
| Profit Margin | -651.62% |
| EBITDA Margin | -933.58% |
| EBIT Margin | -933.58% |
| FCF Margin | -417.2% |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.3% |
| FCF Yield | -2.51% |
Analyst Forecast
The average price target for JANX is $70, which is 135.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $70 |
| Price Target Difference | 135.4% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 28.76 |
| Piotroski F-Score | 2 |